New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
Do errors in the production of antibody genes cause mutations that lead to leukaemias with poor survival rates?
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
High-specificity killing of brain tumour cells using the Zika virus
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?
Re-purposing diabetes medication to treat Ewing's sarcoma
Investigating repurposed drugs to decrease the progression of Ewing’s sarcoma
Evaluating the use of novel treatments in combination with current maintenance therapies for the on-going treatment of high-risk neuroblastomas
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
Exploring a novel drug treatment for osteosarcoma
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Developing a new understanding of the genetics of a rare lymphoma subtype
Identifying whether children with ALCL, ALK- also harbour other genetic changes in their tumours, and what affect this has on how their cancer progresses. This knowledge can help to guide clinicians about how best to treat children with this rarer sub-form of lymphoma.